文献速递炎症性肠病消化道肿瘤与早癌

炎症性肠病患者骨髓增殖性肿瘤风险及对结局的影响:多中心匹配分析

Risk of Myeloproliferative Neoplasms in Patients With Inflammatory Bowel Disease and Impact on Outcomes: A Multi-Centre Matched Analysis.
PubMed 文献 · Aliment Pharmacol Ther · 2026-07-03

本研究基于TriNetX数据库开展两项回顾性队列分析,评估IBD患者发生MPN的风险及IBD-MPN共存的临床结局。匹配后纳入3873例UC-MPN和3474例CD-MPN患者。结果显示IBD患者MPN风险升高,且IBD-MPN共存与更差的IBD相关并发症及恶性肿瘤风险相关。

要点

  • IBD患者发生MPN的风险较非IBD对照升高(UC HR 1.60,CD HR 1.56)。
  • CD-MPN共存与CRC、瘘管、梗阻、穿孔、小肠切除及结肠切除风险升高相关。
  • UC-MPN共存与CRC、PSC及储袋炎风险升高相关;硫嘌呤暴露与MPN风险升高相关。

核心结论

  • IBD与MPN风险升高相关,IBD-MPN共存与更差的IBD相关并发症及恶性肿瘤风险相关。

研究设计与样本

  • 基于TriNetX数据库的两项回顾性队列分析,第一项比较成人UC或CD患者与匹配的非IBD对照的MPN发病风险,第二项评估IBD-MPN共存的5年结局。
  • 匹配后纳入3873例UC-MPN患者和3474例CD-MPN患者。

主要发现

  • 与非IBD匹配对照相比,UC患者MPN发病风险升高(HR 1.60,p=0.01),CD患者MPN发病风险升高(HR 1.56,p<0.001)。
  • CD患者中,MPN共存与CRC(HR 1.52,p=0.012)、肠瘘(HR 2.84,p<0.001)、梗阻(HR 2.05,p<0.001)、穿孔(HR 2.37,p<0.001)、小肠切除(HR 3.69,p<0.001)及结肠切除(HR 2.10,p<0.001)风险升高相关。
  • UC患者中,MPN共存与CRC(HR 1.50,p=0.001)、PSC(HR 1.75,p=0.03)及储袋炎(HR 1.68,p=0.003)风险升高相关。
  • 硫嘌呤暴露与MPN风险升高相关(HR 1.28,p<0.001),而TNF抑制剂、IL-23抑制剂及JAK抑制剂未显示与MPN风险相关。

临床怎么用

  • 对IBD患者应关注MPN发生风险,尤其是使用硫嘌呤者。
  • 对IBD-MPN共存患者应加强监测IBD相关并发症及结直肠癌风险。

局限性

  • 原文未报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inflammatory bowel disease (IBD) and myeloproliferative neoplasms (MPNs) share chronic inflammation and immune dysregulation. AIM: We evaluated the incidence of MPNs among patients with IBD and clinical outcomes of IBD-MPN coexistence. METHODS: Two retrospective cohort analyses were conducted using the TriNetX database. First, adults with ulcerative colitis (UC) or Crohn's disease (CD) were compared with matched non-IBD controls to estimate incident MPN risk. A coexistence second analysis included patients with UC or CD who developed MPNs and then were matched to IBD without MPN controls to assess 5-year outcomes, including IBD-related complications, surgical interventions, colorectal cancer (CRC) and primary sclerosing cholangitis (PSC). Medication subgroup analyses were performed to evaluate associations with MPN risk. RESULTS: After matching, 3873 patients with UC-MPN and 3474 patients with CD-MPN were included. Compared with matched non-IBD controls, incident MPN risk was higher in UC (HR 1.60, p = 0.01) and CD (HR 1.56, p < 0.001). In CD, MPN coexistence was associated with higher risks of CRC (HR 1.52, p = 0.012), intestinal fistula (HR 2.84, p < 0.001), obstruction (HR 2.05, p < 0.001), perforation (HR 2.37, p < 0.001), small bowel resection (HR 3.69, p < 0.001) and colectomy (HR 2.10, p < 0.001). In UC, MPN coexistence was associated with higher risks of CRC (HR 1.50, p = 0.001), PSC (HR 1.75, p = 0.03) and pouchitis (HR 1.68, p = 0.003). Exposure to thiopurines (HR 1.28, p < 0.001) was associated with increased MPN risk, whereas TNF, IL-23 and JAK inhibitors were not. CONCLUSIONS: IBD is associated with increased MPN risk, and IBD-MPNs coexistence is associated with worse IBD-related complications and malignancy risk.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Eldesouki MH, Ibrahim A, Marey MM, et al. Risk of Myeloproliferative Neoplasms in Patients With Inflammatory Bowel Disease and Impact on Outcomes: A Multi-Centre Matched Analysis. Aliment Pharmacol Ther. 2026. PMID: 42394415. doi:10.1111/apt.70779

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。